Immunic, Inc.
IMUX
$1.18
-$0.03-2.08%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 17.99% | 16.10% | 10.68% | 7.64% | 12.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.28% | 10.16% | 12.41% | 5.37% | -1.18% |
| Operating Income | -5.28% | -10.16% | -12.41% | -5.37% | 1.18% |
| Income Before Tax | 3.32% | -6.34% | -6.85% | 1.56% | -7.37% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 3.32% | -6.34% | -6.85% | 1.56% | -7.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.32% | -6.34% | -6.85% | 1.56% | -7.37% |
| EBIT | -5.28% | -10.16% | -12.41% | -5.37% | 1.18% |
| EBITDA | -5.25% | -10.13% | -12.37% | -5.32% | 1.20% |
| EPS Basic | 21.88% | 24.45% | 30.77% | 46.46% | 52.41% |
| Normalized Basic EPS | 20.73% | 22.91% | 29.74% | 46.06% | 54.75% |
| EPS Diluted | 21.88% | 24.45% | 30.77% | 46.46% | 52.41% |
| Normalized Diluted EPS | 20.73% | 22.91% | 29.74% | 46.06% | 54.75% |
| Average Basic Shares Outstanding | 44.06% | 40.34% | 35.81% | 70.37% | 125.95% |
| Average Diluted Shares Outstanding | 44.06% | 40.34% | 35.81% | 70.37% | 125.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |